We are live on ! Find out more
BIO icon

Bio-Rad Laboratories Class A

346 hedge funds and large institutions have $5.94B invested in Bio-Rad Laboratories Class A in 2019 Q1 according to their latest regulatory filings, with 61 funds opening new positions, 132 increasing their positions, 109 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more funds holding in top 10

Funds holding in top 10: 610 (+4)

42% more first-time investments, than exits

New positions opened: 61 | Existing positions closed: 43

34% more capital invested

Capital invested by funds: $4.43B → $5.94B (+$1.51B)

21% more repeat investments, than reductions

Existing positions increased: 132 | Existing positions reduced: 109

5% more funds holding

Funds holding: 328346 (+18)

1.26% more ownership

Funds ownership: 76.95%78.22% (+1.3%)

5% less call options, than puts

Call options by funds: $66.9M | Put options by funds: $70.2M

Holders
346
Holders Change
+18
Holders Change %
+5.49%
% of All Funds
7.49%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.22%
New
61
Increased
132
Reduced
109
Closed
43
Calls
$66.9M
Puts
$70.2M
Net Calls
-$3.36M
Net Calls Change
-$781K
Name Holding Trade Value Shares
Change
Change in
Stake
SC
51
Shellback Capital
Massachusetts
$27.9M +$24.6M +91,177 New
Invesco
52
Invesco
Georgia
$27.6M -$694K -2,572 -3%
GKIM
53
GW&K Investment Management
Massachusetts
$27.2M +$5.77M +21,395 +32%
Principal Financial Group
54
Principal Financial Group
Iowa
$27.1M -$257K -951 -1%
SGA
55
Sector Gamma AS
Norway
$26.7M -$2.51M -9,300 -10%
PPA
56
Parametric Portfolio Associates
Washington
$26M +$1.17M +4,328 +5%
UBS Group
57
UBS Group
Switzerland
$25.7M -$10.6M -39,269 -32%
PAMU
58
Pictet Asset Management (UK)
United Kingdom
$25.5M +$10.6M +39,398 +90%
PCM
59
Portolan Capital Management
Massachusetts
$24.5M +$9.15M +33,903 +73%
CWM
60
CIBC World Markets
New York
$21.9M +$16.1M +59,574 +488%
RA
61
Royce & Associates
New York
$21.6M
Two Sigma Advisers
62
Two Sigma Advisers
New York
$21.5M +$16.9M +62,500 +795%
Artisan Partners
63
Artisan Partners
Wisconsin
$20.3M +$8.93M +33,080 +99%
Assenagon Asset Management
64
Assenagon Asset Management
Luxembourg
$20.2M +$11.9M +43,964 +198%
Arrowstreet Capital
65
Arrowstreet Capital
Massachusetts
$20M +$11.8M +43,752 +202%
TA
66
Tamarack Advisers
California
$19.9M +$1.35M +5,000 +8%
EIP
67
Epoch Investment Partners
New York
$19.3M -$207K -767 -1%
TCIM
68
TIAA CREF Investment Management
New York
$18.9M -$4.84M -17,920 -22%
Ameriprise
69
Ameriprise
Minnesota
$18.5M -$321K -1,189 -2%
RhumbLine Advisers
70
RhumbLine Advisers
Massachusetts
$15.8M -$922K -3,416 -6%
Franklin Resources
71
Franklin Resources
California
$15.8M
O
72
OppenheimerFunds
New York
$15.5M -$4.21M -15,607 -23%
JP Morgan Chase
73
JP Morgan Chase
New York
$15.4M +$1.38M +5,122 +11%
Allianz Asset Management
74
Allianz Asset Management
Germany
$14.8M -$3.68M -13,641 -22%
AIG
75
American International Group
New York
$14.8M +$1.95M +7,229 +18%

BIO Hedge Fund Activity: Q1 2019 in Review

346 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q1 2019, worth a combined $5.94B — up 34% from $4.43B a quarter earlier.

Buyers outnumbered sellers: 61 funds opened new BIO positions and 43 closed out — a net gain of 18 holders — while 132 added to existing stakes and 109 trimmed.

The largest buyer was AllianceBernstein, adding an estimated $34M. The largest seller was TimesSquare Capital Management, exiting entirely with an estimated $142M sold.

  • 346 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q1 2019, up from 328 in Q4 2018.
  • Funds reported $5.94B of Bio-Rad Laboratories Class A stock for Q1 2019, up 34% quarter-over-quarter.
  • 61 funds opened new Bio-Rad Laboratories Class A positions in Q1 2019 and 43 closed out, a net change of +18 holders.
  • The largest Bio-Rad Laboratories Class A buyer in Q1 2019 was AllianceBernstein, an estimated $34M added.
  • The largest Bio-Rad Laboratories Class A seller in Q1 2019 was TimesSquare Capital Management, an estimated $142M sold.

Based on aggregated 13F filings for Q1 2019.